Haemodynamic and Respiratory Effects of Dexmedetomidine as an Adjuvant to Oxycodone Patient‐Controlled Analgesia After Lumbar Spinal Fusion: A Post Hoc Analysis of the DoseRespDex Randomised Controlled Trial
- 1Department of Anaesthesiology and Intensive Care University of Turku Turku Finland
- 2Division of Perioperative Services, Intensive Care and Pain Medicine Turku University Hospital Turku Finland
- 3Department of Biostatistics University of Turku and Turku University Hospital Turku Finland
Abstract
Purpose: Dexmedetomidine has been studied as an adjunct to opioid patient‐controlled analgesia (PCA) because of its opioid‐sparing properties and limited respiratory depression. However, potential dose‐dependent haemodynamic effects should be considered, and data on dexmedetomidine administered via PCA remain limited.
Methods: In this post hoc analysis of a randomised, double‐blind, placebo‐controlled trial, 98 adults undergoing lumbar spinal fusion were randomised 1:1:1:1 to 24‐h PCA with oxycodone 1 mg/mL alone (D0; placebo referring to normal saline replacing dexmedetomidine in the PCA syringe) or combined with dexmedetomidine 2.5 μg/mL (D2), 5 μg/mL (D5) or 10 μg/mL (D10). Outcomes of interest for the present analysis included mean arterial pressure (MAP), heart rate (HR), respiratory parameters and adverse events. Plasma dexmedetomidine concentrations were analysed as a pre‐planned pharmacokinetic sub‐analysis.
Results: Mean changes over time differed significantly between groups for MAP (p = 0.005) and HR (p < 0.001). Plasma dexmedetomidine concentrations increased across the D2, D5 and D10 groups, with observed median peak concentrations of 0.15, 0.31 and 0.55 ng/mL in D2, D5 and D10. Over 72 h, MAP was lower in D5 versus D0 (−11.2 mmHg, 95% confidence interval [CI] −19.9 to −2.5, p = 0.004) and D10 versus D0 (−9.1 mmHg, 95% CI −17.4 to −0.8, p = 0.032). All dexmedetomidine doses reduced HR versus D0 (D2: −10.2; D5: −9.9; D10: −11.9 bpm; all p < 0.01), without differing from each other. Haemodynamic changes resolved by 48 h. No bradycardia occurred, and no between‐group differences were detected in the measured respiratory variables.
Conclusion: Dexmedetomidine as an adjunct to oxycodone PCA produced transient haemodynamic effects without differences in bradycardia or in the measured respiratory variables. Although higher doses resulted in higher plasma concentrations, the magnitude of haemodynamic effects did not follow a clear dose–response pattern in the range studied. Dexmedetomidine 5 μg/mL combined with oxycodone 1 mg/mL may represent a reasonable candidate dose for further investigation.
Editorial Comment: In this post hoc analysis of patients undergoing posterolateral spinal fusion, adjunctive dexamethasone (2.5, 5 or 10 mg/mL), administered alongside oxycodone PCA (1 mg/mL), resulted in a transient, minor decrease in mean arterial blood pressure and in heart rate at the highest doses, with no effect on respiratory parameters and with no adverse events. No correlation between plasma concentrations of dexmedetomidine and haemodynamic parameters was demonstrated.
Trial Registration: NCT02454881, EudraCT 2014‐003252‐31
Related
- Dexmedetomidine versus Subanaesthetic Ketamine for Opioid-sparing Anaesthesia During Lumbar Spine Surgery Under a Standardised Surgical Pleth Index-guided Analgesic Protocol: A Randomised Controlled Trial.
- A randomised, double-blind, multicentre, placebo-controlled phase 3 efficacy, safety, and immunogenicity study of an Ad26.RSV.preF/RSV prefusion F-protein vaccine for the prevention of respiratory syncytial virus-mediated lower respiratory tract disease in adults aged 60 years and older
- Impact of respiratory muscle training on sleep disordered breathing in people with tetraplegia: a sub-analysis of a randomised controlled trial
- Integrating palliative care into respiratory care for people with advanced COPD: study protocol for the international EU PAL-COPD stepped wedge cluster randomised controlled trial of the ICLEAR-EU intervention
- A double-blind randomized controlled trial comparing intranasal dexmedetomidine with and without fentanyl for pediatric premedication
BibTeX
@article{makela2026haemodynamic,
title = {{Haemodynamic and Respiratory Effects of Dexmedetomidine as an Adjuvant to Oxycodone Patient‐Controlled Analgesia After Lumbar Spinal Fusion: A Post Hoc Analysis of the DoseRespDex Randomised Controlled Trial}},
author = {Sanna Mäkelä and Teijo I. Saari and Eliisa Löyttyniemi and Riku Aantaa and Antti Liukas and Panu Uusalo},
journal = {Acta Anaesthesiologica Scandinavica},
year = {2026},
month = oct,
doi = {10.1111/aas.70362},
url = {https://doi.org/10.1111/aas.70362},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Haemodynamic and Respiratory Effects of Dexmedetomidine as an Adjuvant to Oxycodone Patient‐Controlled Analgesia After Lumbar Spinal Fusion: A Post Hoc Analysis of the DoseRespDex Randomised Controlled Trial
AU - Sanna Mäkelä
AU - Teijo I. Saari
AU - Eliisa Löyttyniemi
AU - Riku Aantaa
AU - Antti Liukas
AU - Panu Uusalo
PY - 2026
DA - 2026/10/26
JO - Acta Anaesthesiologica Scandinavica
DO - 10.1111/aas.70362
UR - https://doi.org/10.1111/aas.70362
AB - Purpose: Dexmedetomidine has been studied as an adjunct to opioid patient‐controlled analgesia (PCA) because of its opioid‐sparing properties and limited respiratory depression. However, potential dose‐dependent haemodynamic effects should be considered, and data on dexmedetomidine administered via PCA remain limited. Methods: In this post hoc analysis of a randomised, double‐blind, placebo‐controlled trial, 98 adults undergoing lumbar spinal fusion were randomised 1:1:1:1 to 24‐h PCA with oxycodone 1 mg/mL alone (D0; placebo referring to normal saline replacing dexmedetomidine in the PCA syringe) or combined with dexmedetomidine 2.5 μg/mL (D2), 5 μg/mL (D5) or 10 μg/mL (D10). Outcomes of interest for the present analysis included mean arterial pressure (MAP), heart rate (HR), respiratory parameters and adverse events. Plasma dexmedetomidine concentrations were analysed as a pre‐planned pharmacokinetic sub‐analysis. Results: Mean changes over time differed significantly between groups for MAP (p = 0.005) and HR (p < 0.001). Plasma dexmedetomidine concentrations increased across the D2, D5 and D10 groups, with observed median peak concentrations of 0.15, 0.31 and 0.55 ng/mL in D2, D5 and D10. Over 72 h, MAP was lower in D5 versus D0 (−11.2 mmHg, 95% confidence interval [CI] −19.9 to −2.5, p = 0.004) and D10 versus D0 (−9.1 mmHg, 95% CI −17.4 to −0.8, p = 0.032). All dexmedetomidine doses reduced HR versus D0 (D2: −10.2; D5: −9.9; D10: −11.9 bpm; all p < 0.01), without differing from each other. Haemodynamic changes resolved by 48 h. No bradycardia occurred, and no between‐group differences were detected in the measured respiratory variables. Conclusion: Dexmedetomidine as an adjunct to oxycodone PCA produced transient haemodynamic effects without differences in bradycardia or in the measured respiratory variables. Although higher doses resulted in higher plasma concentrations, the magnitude of haemodynamic effects did not follow a clear dose–response pattern in the range studied. Dexmedetomidine 5 μg/mL combined with oxycodone 1 mg/mL may represent a reasonable candidate dose for further investigation. Editorial Comment: In this post hoc analysis of patients undergoing posterolateral spinal fusion, adjunctive dexamethasone (2.5, 5 or 10 mg/mL), administered alongside oxycodone PCA (1 mg/mL), resulted in a transient, minor decrease in mean arterial blood pressure and in heart rate at the highest doses, with no effect on respiratory parameters and with no adverse events. No correlation between plasma concentrations of dexmedetomidine and haemodynamic parameters was demonstrated. Trial Registration: NCT02454881, EudraCT 2014‐003252‐31
SN - 0001-5172
SN - 1399-6576
ER -